Blue Shield of California CEO: Trump insurance plan won’t help competition

Allowing insurance companies to sell health plans across state lines is “perplexing” to Paul Markovich, CEO of Blue Shield of California, the state’s largest insurer.

Markovich was critical of this proposal from President-elect Donald Trump in an interview with California Healthline, casting doubts on Trump’s claims it would increase competition among insurers and drive down premiums.

“It will push health plans to find the regulatory body or state with the fewest number of regulations,” Markovich said. “It’s a race to the lowest common denominator and least rich benefits. That is what we want to avoid, and I don’t think it will do much to increase competition. I find it perplexing.”

The Affordable Care Act already gives states the ability to allow this practice by joining into “healthcare choice compacts,” but only three—Georgia, Kentucky and Maine—have passed it into law, with none entering into agreements with other states. Insurers haven’t been pushing for the compacts because of the struggles creating an adequate network in an unfamiliar state.

For more on why Markovich and other major California insurers feel Trump may have to change his mind about certain healthcare reforms, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.